This new meta-analysis indicates that ‘no further trials are needed to better evaluate the efficacy of PUFAs in preventing death related to CVD”. A total of 100,609 patients were analyzed. Reduction in mortality due to cardiovascular issues was statistically significant with a relative risk of 0.937, CI 0.88-0.98, P=0.018. Is it time to put this decades-long debate to bed? We think so.
Click here to read more.